2. Search Result
Search Result
Results for "

Prostaglandin I2

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Peptides

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-A0126A
    Epoprostenol sodium

    Prostaglandin I2 sodium salt; Prostacyclin sodium salt; Flolan

    		 Endogenous Metabolite Cardiovascular Disease
    Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium
  • HY-A0126AR
    Epoprostenol sodium (Standard)

    Prostaglandin I2 sodium salt (Standard); Prostacyclin sodium salt (Standard); Flolan (Standard)

    		 Endogenous Metabolite Cardiovascular Disease
    Epoprostenol (sodium) (Standard) is the analytical standard of Epoprostenol (sodium). This product is intended for research and analytical applications. Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH) . Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation .
    Epoprostenol sodium (Standard)
  • HY-130594
    6α-Prostaglandin I1

    6α-PGI1

    		 Others Others
    6α-Prostaglandin I1 (6α-PGI1) is an analogue of prostacycline I2 (PGI2) and is resistant to hydrolysis in aqueous solution .
    6α-<em>Prostaglandin</em> I1
  • HY-101692
    AZ-1355

    		Prostaglandin Receptor Metabolic Disease Endocrinology
    AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro.
    AZ-1355
  • HY-129199
    U-51605

    		Others Cardiovascular Disease
    U-51605 is a platelet aggregation inhibitor and inhibits thromboxane synthesis. U-51605 is also a prostaglandin I2 synthase inhibitor and can inhibit the retinal vasodilation response induced by NO donors (such as NOR3) .
    U-51605
  • HY-130522
    6β-Prostaglandin I1

    6β-PGI1

    		 Others Others
    6β-Prostaglandin I1 (6β-PGI1) is an analog of prostaglandin I2 (PGI2) that is resistant to hydrolysis in aqueous solutions. 6β-Prostaglandin I1 can reduce gastric acid secretion with an ID50 (dose causing 50% inhibition) of approximately 3.0 μg/kg/min (intravenous injection) .
    6β-<em>Prostaglandin</em> I1
  • HY-106961
    ONO 1301

    ONO-AP 500-02

    		 Prostaglandin Receptor Cardiovascular Disease
    ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
    ONO 1301
  • HY-106961A
    (Z)-ONO 1301

    (Z)-ONO-AP 500-02

    		 Others Cardiovascular Disease
    (Z)-ONO 1301 is the isomer of ONO 1301 (HY-106961), and can be used as an experimental control. ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig .
    (Z)-ONO 1301
  • HY-124428
    ASP6537

    FK881

    		 COX Cardiovascular Disease
    ASP6537 is a potent and selective rhCOX-1 inhibitor with an IC50 of 0.703 nM. ASP6537 has the potential for cardiovascular disease research .
    ASP6537

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: